Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

The genetics of drug dependence: tobacco addition

Article Abstract:

Genetic factors may partially determine an individual's smoking habits and whether or not they can quit. Most individuals try cigarette smoking at some time in their life, but only some become addicted to cigarettes. Drug addiction is caused by the complex interaction of a variety of factors, including genetic predisposition. Research studies have found that genetic factors can either make a person less vulnerable or more vulnerable to alcoholism. Very little research has been done into the genetic aspects of tobacco and other types of drug addiction. A research study of the smoking habits of male twins over a 16-year period found that tobacco addiction may be partially determined by genetic factors. Men who were identical twins were more likely to have the same smoking habits as their twin than those who were fraternal twins. Identical twins also were more likely to be similar in their ability to quit smoking than fraternal twins.

Author: Benowitz, Neal L.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1992
Genetic aspects, Smoking, Tobacco

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Treating tobacco addiction - nicotine or no nicotine?

Article Abstract:

The antidepressant drug bupropion may be a safe alternative to nicotine patches and gums in smokers who want to quit. In a 1997 study, 44% of the smokers who took 300 milligrams of the drug daily quit smoking. It is not clear how antidepressants help smokers quit. Smokers have higher rates of depression than non-smokers and nicotine may have an antidepressant effect. Nicotine addiction may involve abnormal neurotransmitter levels, which could be restored to normal by antidepressants. Nicotine patches and gums are not always effective and many patients may prefer using a non-nicotine medication.

Author: Benowitz, Neal L.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
Usage, Evaluation, Smoking cessation programs, Smoking cessation, Antidepressants

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids

Article Abstract:

Dietary supplements containing ephedra may have serious side effects. A review of 140 reports of adverse effects caused by ephedra found that hypertension was the most common side effect, followed by heart palpitations, rapid heartbeat, stroke, and seizures.

Author: Benowitz, Neal L., Haller, Christine A.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
Complications and side effects, Ephedra

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Editorial
Similar abstracts:
  • Abstracts: The new AIDS case definition: implications for San Francisco. Tracing a Syphilis Outbreak Through Cyberspace
  • Abstracts: Ashworth workers suspended as inquiry slams conditions. Wrestling with demons ended in tragedy. Ashworth: will isolating the patient do any good?
  • Abstracts: Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males
  • Abstracts: Practice nurses' use of evidence-based research. Promoting excellence in the care of older people: case report 3
  • Abstracts: The effect of magnesium sulfate on bleeding time in pregnancy. Histologic chorioamnionitis is associated with fetal growth restriction in term and preterm infants
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.